14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RXRX vs DGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Recursion Pharmaceuticals, Inc. (RXRX) is the stronger overall head-to-head candidate over Diginex Limited (DGNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RXRX carries a Unified Composite Score of 49.5/100 (HOLD) at $2.90 (N/M Forward P/E, -734.2% operating margin), whereas DGNX carries 49.7/100 (HOLD) at $1.18 (N/M Forward P/E, -546.3% operating margin).
Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile DGNX is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RXRX vs DGNX. Trailing 12-month operating profitability (RXRX -734.2% vs DGNX -546.3%) and valuation multiples (RXRX N/M vs DGNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Software - Application value chain with $63.7M market capitalization and -546.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RXRX vs DGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Recursion Pharmaceuticals, Inc. (RXRX) is the stronger overall head-to-head candidate over Diginex Limited (DGNX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RXRX carries a Unified Composite Score of 49.5/100 (HOLD) at $2.90 (N/M Forward P/E, -734.2% operating margin), whereas DGNX carries 49.7/100 (HOLD) at $1.18 (N/M Forward P/E, -546.3% operating margin). Technical & Structure Timing Caution: RXRX is currently in a Breakdown options structure phase (RSI 35.7); meanwhile DGNX is in a Breakdown options structure phase (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RXRX leads the Growth & Scale pillar: RXRX posts +258.5% YoY revenue growth and +0.0% YoY earnings growth on $68M TTM revenue (N/A gross margin, -734.2% operating margin), compared with DGNX at +3.3% YoY revenue growth and +0.0% YoY earnings growth on $3.6M TTM revenue (100.0% gross margin, -546.3% operating margin). On trailing 12-month operating scale, RXRX generates $68M in USD-normalized revenue versus $3.6M for DGNX. In operating R&D and SG&A reinvestment, RXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DGNX.
DGNX screens cheaper on headline valuation multiples. RXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 23.5x EV/Revenue (unreported FCF margin), whereas DGNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RXRX (-48.7% ROE) versus DGNX (-250.4% ROE) capital efficiency.
In options market volatility and institutional positioning, RXRX carries 92.3% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 85% Vol realized risk). By comparison, DGNX carries 392.0% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.04β · 100% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.